ImmunityBio, Inc. IBRX

8.44 (0.20) (2.31%) as of 25 Sep
Market cap
$9.2B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
16.08 121.07 4,284.97 7,948.01 2,533.77 8,307.96 630.50 1,953.05 7,843.51 11,011.27
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(25.88) (20.97) (23.12) (21.02) (33.03) (87.26) (13.14) (6.54) (25.88) (45.06)
P/B ratio
0.00 0.00 0.00 0.00 0.00 0.00 11.50 0.63 1.61 1.65
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 11.56 0.63 1.63 1.68
EV/Sales
18.20 142.69 4,963.20 10,306.30 2,845.85 8,581.04 613.79 818.49 5,365.04 6,536.36
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(6.76) (5.38) (8.42) (7.33) (9.69) (30.23) (8.89) (0.61) (4.95) (7.45)
EV/FCF
(6.68) (5.28) (7.77) (5.66) (9.23) (29.94) (8.65) (0.51) (2.89) (6.37)
Quick Ratio
4.62 2.77 4.57 0.22 0.86 1.42 4.49 3.17 6.20 16.06
Current Ratio
5.10 3.36 5.05 0.28 0.91 1.64 4.82 3.26 6.35 16.34
Net Debt/EBITDA
(0.97) (1.03) (1.38) (1.79) (0.92) (0.80) 0.26 0.76 1.37 1.65
Debt/Assets
95.06% 120.62% 135.10% 185.78% 129.79% 118.02% 10.37% 3.80% 0.94% 0.81%
Debt/Equity
(0.95) (0.95) (1.16) (1.50) (2.50) (2.20) 0.12 0.05 0.01 0.01
Asset Turnover
0.26 0.03 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00
Operating CF/Net income
0.87 0.95 0.63 0.81 0.79 0.77 0.96 0.66 0.51 0.32
Capex/Depreciation
(0.25) (0.17) (0.49) (2.77) (0.89) (0.12) (0.29) (1.27) (4.86) (1.13)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
71.15% 77.01% 112.61% 120.09% 191.38% (20,269.62%) (118.32%) (52.75%) (37.65%) (37.21%)
ROA
(79.43%) (93.21%) (134.56%) (100.22%) (100.48%) (121.73%) (97.07%) (44.51%) (33.96%) (35.31%)
ROIC
0.00% 0.00% 0.00% (189.00%) (433.97%) (295.46%) (116.43%) (78.07%) (66.58%) (80.17%)
Return on Tangible Assets
(95.65%) (155.05%) (152.72%) 192.30% (719.26%) (191.05%) (150.70%) (69.53%) (51.20%) (57.12%)
Average Days of Receivables
137.16 58.42 0.00 2,874.38 520.93 312.51 50.22 94,496.17 10,203.78 22,132.27
Research and Development Expense of Revenue
192.92% 1,289.55% 37,357.88% 103,395.42% 20,980.51% 23,059.01% 5,086.15% 118,548.94% 93,431.11% 66,256.82%
Selling, General and Administrative Expense of Revenue
132.41% 1,144.68% 20,839.23% 42,795.00% 14,481.37% 11,788.10% 2,109.72% 90,889.36% 126,935.56% 216,797.73%
Intangible Assets out of Total Assets
0.03 0.04 0.03 0.06 0.00 0.01 0.00 0.00 0.01 0.02
Share Based Compensation of Revenue
32.49% 233.52% 7,904.02% 16,741.25% 6,122.16% 361.49% 155.36% 49,748.94% 82,215.56% 167,845.45%
Graham Net Nets
(0.38) (0.38) (0.30) (0.35) (0.16) (0.05) 0.02 0.58 0.29 0.37
Graham Number
2.15 3.07 5.48 5.15 3.56 2.05 0.00 0.00 0.00 0.00
Earnings Yield
(19.19%) (23.44%) (22.14%) (21.95%) (14.75%) (4.46%) (18.73%) (105.22%) (27.40%) (24.87%)
Free Cash Flow Yield
(16.95%) (22.30%) (14.91%) (22.90%) (12.17%) (3.45%) (11.25%) (82.87%) (23.68%) (9.32%)
Revenue per Share
0.12 0.02 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00
Operating CF per Share
(0.33) (0.56) (0.72) (0.84) (0.70) (0.46) (0.42) (0.80) (0.61) (0.47)
Capex per Share
0.00 (0.01) (0.06) (0.25) (0.03) 0.00 (0.01) (0.16) (0.43) (0.08)
Free Cash Flow per Share
(0.34) (0.57) (0.78) (1.09) (0.74) (0.46) (0.43) (0.96) (1.04) (0.55)
Cash per Share
0.26 0.21 0.52 0.27 0.81 0.25 0.14 0.94 1.59 2.43
Shareholders Equity per Share
(0.54) (0.70) (1.15) (1.12) (0.63) (0.31) 0.33 1.85 2.72 3.58
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.54) (0.70) (1.15) (1.12) (0.63) (0.31) 0.33 1.85 2.72 3.58
Free Cash Flow
(308.78) (398.12) (397.34) (436.90) (287.48) (173.39) (156.20) (76.07) (83.59) (45.15)
Working Capital
253.12 129.64 235.80 (360.28) (34.65) 43.58 44.20 61.51 111.59 192.59
Capital Expenditures
(3.85) (6.89) (30.58) (99.39) (13.06) (1.67) (4.09) (12.69) (34.81) (6.56)
Net Current Asset Value
(686.60) (686.48) (796.30) (671.60) (378.48) (228.16) 33.31 52.83 100.86 181.07
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.47 49.17 414.13 13.99 2.76 1.86 270.00 773.67 149.09
Net Profit Margin
(310.18%) (2,804.77%) (93,761.41%) (173,569.58%) (37,129.55%) (36,669.59%) (7,165.17%) (204,736.17%) (214,273.33%) (274,565.91%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.14 0.29 0.42 0.25 0.18 0.19 0.23 0.13 0.09 0.31
Cash ROIC
(190.25%) (427.60%) (141.64%) (145.57%) (52.40%) (102.27%) (113.59%) (61.77%) (35.93%) (11.62%)
Accounts Receivable Turnover
5.04 6.94 0.00 0.15 1.01 1.47 0.35 0.01 0.02 0.03
Accounts Payable Turnover
0.11 0.00 0.00 1.49 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.16 — — 0.00 — — — — — —
Average Days of Payables
3,382.43 0.00 0.00 317.08 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
441.10 0.00 — 0.00 — — — — — —
Average Receivables
22.47 2.13 — 1.61 0.93 0.41 6.24 6.71 1.96 1.47
Average Payables
6.85 7.96 15.11 16.22 11.46 6.63 2.27 4.33 4.96 3.07
Average Inventory
4.59 — — — — — — — — —
Average Assets
442.42 443.69 433.40 415.63 345.15 182.25 162.54 216.20 283.97 342.17
Average Common Equity
(493.85) (537.03) (517.88) (346.87) (181.20) 1.09 133.34 182.43 256.13 324.71

Fold the line items

Columns are period end dates